Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Apr
03
Today In Oncology
Financial Hardship and Late-Stage Cancer Diagnosis
Agent Orange Exposure Linked to MDS Risk and Progression
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
Low-Risk Endometrial Cancer Does a Lack of Adjuvant Therapy Affect Survival
ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo